0.5438
5.61%
+0.0289
After Hours:
.5558
0.012
+2.21%
Sangamo Therapeutics Inc stock is currently priced at $0.5438, with a 24-hour trading volume of 1.31M.
It has seen a +5.61% increased in the last 24 hours and a -10.50% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.518 pivot point. If it approaches the $0.557 resistance level, significant changes may occur.
Previous Close:
$0.5149
Open:
$0.5237
24h Volume:
1.31M
Market Cap:
$112.84M
Revenue:
$176.23M
Net Income/Loss:
$-257.83M
P/E Ratio:
-0.375
EPS:
-1.45
Net Cash Flow:
$-246.00M
1W Performance:
+10.30%
1M Performance:
-10.50%
6M Performance:
-7.96%
1Y Performance:
-63.99%
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Name
Sangamo Therapeutics Inc
Sector
Industry
Phone
510-970-6000
Address
501 Canal Boulevard, Richmond, CA
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-28-23 | Downgrade | BofA Securities | Neutral → Underperform |
Feb-27-23 | Upgrade | Wedbush | Neutral → Outperform |
Jan-06-23 | Downgrade | BofA Securities | Buy → Neutral |
Jun-13-22 | Resumed | Wedbush | Neutral |
May-04-21 | Initiated | RBC Capital Mkts | Outperform |
Jan-07-21 | Resumed | Guggenheim | Neutral |
Jan-06-21 | Initiated | Stifel | Hold |
Dec-16-20 | Resumed | H.C. Wainwright | Buy |
Sep-08-20 | Initiated | BofA Securities | Buy |
Jul-07-20 | Initiated | SunTrust | Buy |
Aug-26-19 | Initiated | H.C. Wainwright | Buy |
Nov-14-18 | Downgrade | JP Morgan | Overweight → Neutral |
Nov-09-18 | Downgrade | Guggenheim | Buy → Neutral |
Oct-10-18 | Initiated | Guggenheim | Buy |
Jun-20-18 | Initiated | BofA/Merrill | Buy |
Nov-15-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
Jun-22-17 | Resumed | Jefferies | Buy |
Nov-01-16 | Downgrade | Wedbush | Outperform → Neutral |
Oct-19-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
Dec-04-15 | Initiated | Wells Fargo | Outperform |
Oct-23-15 | Resumed | Jefferies | Buy |
May-03-13 | Initiated | BioLogic Equity Research | Sell |
Feb-23-11 | Reiterated | JMP Securities | Mkt Outperform |
Jul-29-10 | Reiterated | Wedbush | Outperform |
Oct-19-09 | Initiated | Brean Murray | Sell |
Oct-07-09 | Reiterated | Leerink Swann | Outperform |
Aug-25-09 | Reiterated | JMP Securities | Mkt Outperform |
View All
Sangamo Therapeutics Inc Stock (SGMO) Latest News
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
Benzinga
4 Analysts Assess Sangamo Therapeutics: What You Need To Know
Benzinga
Why Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Benzinga
Deep Dive Into Sangamo Therapeutics Stock: Analyst Perspectives (4 Ratings)
Benzinga
2 Low-Priced Gene Therapy Stocks to Speculate On
Investing.com
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Sangamo Therapeutics Inc Stock (SGMO) Financials Data
Sangamo Therapeutics Inc (SGMO) Revenue 2024
SGMO reported a revenue (TTM) of $176.23 million for the quarter ending December 31, 2023, a +58.34% rise year-over-year.
Sangamo Therapeutics Inc (SGMO) Net Income 2024
SGMO net income (TTM) was -$257.83 million for the quarter ending December 31, 2023, a -34.09% decrease year-over-year.
Sangamo Therapeutics Inc (SGMO) Cash Flow 2024
SGMO recorded a free cash flow (TTM) of -$246.00 million for the quarter ending December 31, 2023, a -0.90% decrease year-over-year.
Sangamo Therapeutics Inc (SGMO) Earnings per Share 2024
SGMO earnings per share (TTM) was -$1.47 for the quarter ending December 31, 2023, a -17.60% decline year-over-year.
About Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc. focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for Hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); preclinical programs in other LSDs; and research stage programs in central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and Shire International GmbH to develop preclinical development program in Huntington's disease, as well as license agreements with Sigma-Aldrich Corporation to develop laboratory research reagents and Dow AgroSciences, LLC to modify the protein expression of plant cells and plants. The company also has a research collaboration and license agreement with Pfizer Inc; and collaboration with Kite for developing ex vivo cell therapies in oncology. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Cap:
|
Volume (24h):